FDA 483 - ULTRAVISION CORPORATION - May 20, 2022

An FDA inspection of ULTRAVISION CORPORATION in North Palm Beach, FL, revealed significant deficiencies across its quality system. The firm failed to establish adequate procedures for design control, quality audits, management review, training, MDR reporting, complaint handling, and purchasing controls. These issues indicate a broad lack of adherence to regulatory requirements for medical device manufacturing.